Back to results
US 11,896,604 B2Granted
Composition comprising HMSs/HMOs and use thereof
AssigneeGlycom A/S
InventorsBruce McConnell, Emma Elison, Louise Kristine Vigsnæs
Life of this patent
Estimating the term…
Abstract
The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.
Claims20
A method comprising:
- selecting a non-infant human experiencing diarrhea-predominant irritable bowel syndrome (“IBS-D”);
- selecting a daily dose comprising an effective amount of one or more neutral human milk oligosaccharides (HMOs) selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof, the amount effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human;
- and
- increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and improving stool consistency in the non-infant human by administering to the non-infant human the daily dose of from about 3 g to about 10 g of the one or more HMOs.
1 more element
A method comprising:
- selecting a non-infant human experiencing lactose intolerance and one or more gastrointestinal symptoms of lactose intolerance, the gastrointestinal symptoms selected from diarrhea, abdominal pain, cramping, bloating, and flatulence;
- selecting a daily dose comprising an effective amount of one or more neutral human milk oligosaccharides (HMOs) selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof, the amount effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human;
- and
- increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and reducing at least one of the one or more gastrointestinal symptoms of the lactose intolerance by administering to the non-infant human the daily dose of from about 3 g to about 10 g of the one or more HMOs during an initial treatment period.
1 more element
A method comprising:
- selecting a non-infant human commencing an antibiotic therapy;
- selecting a daily dose comprising an effective amount of one or more neutral human milk oligosaccharides (HMOs) selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof, the amount effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human;
- and
- increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and reducing the likelihood of the non-infant human experiencing gastrointestinal dysbiosis, diarrhea, or both, associated with the antibiotic therapy by administering to the non-infant human the daily dose of from about 3 g to about 10 g of the one or more neutral HMOs.
1 more element
Dependencies are inferred from the claim text.